Biotechnology and Pharmaceuticals

March 20, 2020

Buy ($175)

Companies covered: Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY), Allogene Therapeutics (NASDAQ:ALLO), CRISPR Therapeutics AG (NASDAQ:CRSP), Precision BioSciences (NASDAQ:DTIL), Celyad SA (ADR) (NASDAQ:CYAD), Cellectis S.A. (NASDAQ:CLLS), Pfizer, Inc. (NYSE:PFE), Sangamo Therapeutics, Inc. (NASDAQ:SGMO), Selecta Biosciences Inc (NASDAQ:SELB), Horizon Pharma plc (NASDAQ:HZNP), Calyxt (NASDAQ:CLXT), Amgen Inc. (NASDAQ:AMGN), Novartis AG (NYSE:NVS), Allergan, Inc. (NYSE:AGN), AbbVie Inc. (NYSE:ABBV), Bristol-Myers Squibb Company (NYSE:BMY), H. Lundbeck A/S (ADR) (OTCMKTS:HLUYY), Karuna Therapeutics (NASDAQ:KRTX), Satsuma Pharmaceuticals (NASDAQ:STSA), BioLife Solutions, Inc. (NASDAQ:BLFS), Brooks Automation, Inc. (NASDAQ:BRKS), Catalent, Inc. (NYSE:CTLT), CryoPort Inc. (NASDAQ:CYRX), Repligen Corporation (NASDAQ:RGEN), Bio-Techne Corp (NASDAQ:TECH), Biogen Inc. (NASDAQ:BIIB), Denali Therapeutics (NASDAQ:DNLI), Amicus Therapeutics, Inc. (NASDAQ:FOLD), WuXi Biologics Cayman (OTCMKTS:WXIBF), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Rocket Pharmaceuticals (NASDAQ:RCKT), Novocure Ltd. (NASDAQ:NVCR), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Moderna (NASDAQ:MRNA), Arcturus Therapeutics Ltd. (NASDAQ:ARCT), SCYNEXIS, Inc. (NASDAQ:SCYX), Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), Omeros Corporation (NASDAQ:OMER), Medicenna Therapeutics Corp. (OTCMKTS:MDNAF), Veru (NASDAQ:VERU), Chiasma (NASDAQ:CHMA), Atreca (NASDAQ:BCEL), Monopar Therapeutics (NASDAQ:MNPR), Vaxart (NASDAQ:VXRT), CEL-SCI Corporation (NYSEAMERICAN:CVM), ProMIS Neurosciences (TSE:PMN), Fortress Biotech, Inc. (NASDAQ:FBIO), Achieve Life Sciences (NASDAQ:ACHV), AzurRx BioPharma (NASDAQ:AZRX), Passage Bio (NASDAQ:PASG), Pressure BioSciences Inc. (OTCMKTS:PBIO), Sensus Healthcare (NASDAQ:SRTS), Nanobiotix (EPA:NANO), Protagonist Therapeutics, Inc. (NASDAQ:PTGX), Quick-Med Technologies Inc. (OTCMKTS:QMDT), RespireRx Pharmaceuticals Inc. (OTCMKTS:RSPI), Mesoblast Limited (NASDAQ:MESO), Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

Biotechnology and Pharmaceuticals

October 04, 2019

Buy ($175)

Companies covered: Spark Therapeutics, Inc. (NASDAQ:ONCE), Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY), Audentes Therapeutics (NASDAQ:BOLD), Novartis AG (NYSE:NVS), bluebird bio, Inc. (NASDAQ:BLUE), Novocure Ltd. (NASDAQ:NVCR), Mallinckrodt plc (NYSE:MNK), Endo International plc (NASDAQ:ENDP), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Insys Therapeutics, Inc. (NASDAQ:INSY), Johnson & Johnson (NYSE:JNJ), Recro Pharma, Inc. (NASDAQ:REPH), Flexion Therapeutics, Inc. (NASDAQ:FLXN), Galapagos NV (NASDAQ:GLPG), Amneal Pharmaceuticals (NYSE:AMRX), Indivior PLC (OTCMKTS:IZQVF), Reckitt Benckiser Group plc (OTCMKTS:RBGPF), Quick-Med Technologies Inc. (OTCMKTS:QMDT), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Oncternal Therapeutics, Inc. (NASDAQ:ONCT), RespireRx Pharmaceuticals Inc. (OTCMKTS:RSPI), BioXcel Therapeutics, Inc. (NASDAQ:BTAI), Phio Pharmaceuticals Corp. (NASDAQ:PHIO), AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)

Medical Devices

July 12, 2019

Buy ($175)

Companies covered: Abbott Laboratories (NYSE:ABT), Boston Scientific Corporation (NYSE:BSX), Stryker Corporation (NYSE:SYK), Medtronic, Inc. (NYSE:MDT), Intuitive Surgical, Inc. (NASDAQ:ISRG), Hill-Rom Holdings Inc (NYSE:HRC), Varian Medical Systems, Inc. (NYSE:VAR), Zimmer Biomet Holdings Inc. (NYSE:ZBH), Johnson & Johnson (NYSE:JNJ), DexCom, Inc. (NASDAQ:DXCM), Tandem Diabetes Care, Inc. (NASDAQ:TNDM), Uber Technologies (NYSE:UBER), Lyft (NASDAQ:LYFT), Novocure Ltd. (NASDAQ:NVCR), Vericel Corporation (NASDAQ:VCEL), OrthoPediatrics Corp. (NASDAQ:KIDS), ConforMIS Inc (NASDAQ:CFMS), Spine Injury Solutions (OTCMKTS:SPIN), Glaukos Corp (NYSE:GKOS), Globus Medical, Inc. (NYSE:GMED), AxoGen, Inc. (NASDAQ:AXGN), MediWound Ltd. (NASDAQ:MDWD), Smith & Nephew SNATS, Inc. (NYSE:SNN), Allergan, Inc. (NYSE:AGN), Ocular Therapeutix, Inc. (NASDAQ:OCUL), Becton, Dickinson and Company (NYSE:BDX), Invacare Corporation (NYSE:IVC), STERIS Corporation (NYSE:STE), Avanos Medical (NYSE:AVNS), Cardinal Health, Inc. (NYSE:CAH), General Electric Company (NYSE:GE), Koninklijke Philips N.V. (NYSE:PHG), Kimberly-Clark Corporation (NYSE:KMB), Owens & Minor, Inc. (NYSE:OMI), AngioDynamics, Inc. (NASDAQ:ANGO), Teleflex Incorporated (NYSE:TFX), MannKind Corporation (NASDAQ:MNKD), Sanofi (NYSE:SNY), Pfizer, Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), United Therapeutics Corporation (NASDAQ:UTHR), MYOS Corporation (NASDAQ:MYOS), Amazon.com, Inc. (NASDAQ:AMZN), NanoVibronix Inc. (NASDAQ:NAOV), iCAD, Inc. (NASDAQ:ICAD), Hologic, Inc. (NASDAQ:HOLX), Aethlon Medical Inc. (NASDAQ:AEMD), Quanterix Corporation (NASDAQ:QTRX), electroCore, Inc. (NASDAQ:ECOR), PAVmed Inc. (NASDAQ:PAVM), Digipath, Inc. (OTCMKTS:DIGP), OraSure Technologies, Inc. (NASDAQ:OSUR)

Proprietary Genome Editing Platforms

March 22, 2019

Buy ($175)

Companies covered: Celyad SA (ADR) (NASDAQ:CYAD), bluebird bio, Inc. (NASDAQ:BLUE), Spark Therapeutics, Inc. (NASDAQ:ONCE), Gilead Sciences, Inc. (NASDAQ:GILD), Novartis AG (NYSE:NVS), Rocket Pharmaceuticals (NASDAQ:RCKT), Biogen Inc. (NASDAQ:BIIB), Ionis Pharmaceuticals Inc (NASDAQ:IONS), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Sangamo Therapeutics, Inc. (NASDAQ:SGMO), Pfizer, Inc. (NYSE:PFE), Abeona Therapeutics (NASDAQ:ABEO), LogicBio Therapeutics (NASDAQ:LOGC), Krystal Biotech (NASDAQ:KRYS), Global Blood Therapeutics (NASDAQ:GBT), Lonza Group AG (ADR) (OTCMKTS:LZAGY), Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY), Celgene Corporation (NASDAQ:CELG), Bristol-Myers Squibb Company (NYSE:BMY), uniQure N.V. (NASDAQ:QURE), Sarepta Therapeutics, Inc. (NASDAQ:SRPT), CRISPR Therapeutics AG (NASDAQ:CRSP), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Voyager Therapeutics (NASDAQ:VYGR), Lysogene SA (EPA:LYS), Nightstar Therapeutics PLC (NASDAQ:NITE), Denali Therapeutics (NASDAQ:DNLI), Arcturus Therapeutics Ltd. (NASDAQ:ARCT), NeuBase Therapeutics, Inc. (NASDAQ:NBSE), Bio-Path Holdings, Inc. (NASDAQ:BPTH), Regenxbio Inc (NASDAQ:RGNX), PTC Therapeutics, Inc. (NASDAQ:PTCT), Amicus Therapeutics, Inc. (NASDAQ:FOLD), Axovant Sciences Ltd. (NASDAQ:AXGT), Ophthotech Corporation (NASDAQ:OPHT), MeiraGTx Holdings PLC (NASDAQ:MGTX), Editas Medicine (NASDAQ:EDIT), Intellia Therapeutics (NASDAQ:NTLA), Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Illumina, Inc. (NASDAQ:ILMN), Amazon.com, Inc. (NASDAQ:AMZN), Cellectis S.A. (NASDAQ:CLLS), AquaBounty Technologies, Inc. (NASDAQ:AQB), Biocon Ltd. (BOM:532523), Invitae Corp. (NYSE:NVTA)

Biotechnology and Pharmaceuticals

March 15, 2019

Buy ($175)

Companies covered: Gilead Sciences, Inc. (NASDAQ:GILD), CRISPR Therapeutics AG (NASDAQ:CRSP), Editas Medicine (NASDAQ:EDIT), bluebird bio, Inc. (NASDAQ:BLUE), ProQR Therapeutics N.V. (NASDAQ:PRQR), Intellia Therapeutics (NASDAQ:NTLA), Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), Genfit SA (OTCMKTS:GNFTF), Viking Therapeutics (NASDAQ:VKTX), InflaRx NV (NASDAQ:IFRX), ChemoCentryx, Inc. (NASDAQ:CCXI), Madrigal Pharmaceuticals (NASDAQ:MDGL), Celgene Corporation (NASDAQ:CELG), VBI Vaccines Inc. (NASDAQ:VBIV), Acer Therapeutics (NASDAQ:ACER), SCYNEXIS, Inc. (NASDAQ:SCYX), Johnson & Johnson (NYSE:JNJ), Takeda Pharmaceutical Co. Ltd. (NYSE:TAK), Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Proteon Therapeutics, Inc. (NASDAQ:PRTO), Cellectar Biosciences, Inc. (NASDAQ:CLRB), Chiasma (NASDAQ:CHMA), Veru (NASDAQ:VERU), Arcturus Therapeutics Ltd. (NASDAQ:ARCT), Medicenna Therapeutics Corp. (OTCMKTS:MDNAF), Catabasis Pharmaceuticals Inc (NASDAQ:CATB), Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Wave Life Sciences Ltd (NASDAQ:WVE), Merck & Company, Inc. (NYSE:MRK), AbbVie Inc. (NYSE:ABBV), Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Solid Biosciences (NASDAQ:SLDB), Pfizer, Inc. (NYSE:PFE), Biogen Inc. (NASDAQ:BIIB), Amgen Inc. (NASDAQ:AMGN), MacroGenics, Inc. (NASDAQ:MGNX), Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Astrazeneca PLC (NYSE:AZN), Novartis AG (NYSE:NVS), Strongbridge Biopharma plc (NASDAQ:SBBP), Moderna (NASDAQ:MRNA), Spark Therapeutics, Inc. (NASDAQ:ONCE), Mustang Bio, Inc. (NASDAQ:MBIO), CEL-SCI Corporation (NYSEAMERICAN:CVM), Eli Lilly and Company (NYSE:LLY), vTv Therapeutics Inc (NASDAQ:VTVT), Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), ProMIS Neurosciences (TSE:PMN), BioPorto A/S (CPH:BIOPOR), InMed Pharmaceuticals, Inc. (OTCMKTS:IMLFF), Protagonist Therapeutics, Inc. (NASDAQ:PTGX), Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), True Leaf Medicine International Ltd. (OTCMKTS:TRLFF), Auris Medical Holding AG (NASDAQ:EARS), Cellectis S.A. (NASDAQ:CLLS), Celyad SA (ADR) (NASDAQ:CYAD), Adaptimmune Therapeutics plc (NASDAQ:ADAP), Mirati Therapeutics, Inc. (NASDAQ:MRTX), Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), T2 Biosystems, Inc. (NASDAQ:TTOO), Nightstar Therapeutics PLC (NASDAQ:NITE), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Blueprint Medicines Corp. (NASDAQ:BPMC), Genocea Biosciences, Inc. (NASDAQ:GNCA), Bristol-Myers Squibb Company (NYSE:BMY), Verastem, Inc. (NASDAQ:VSTM), Bayer AG (ADR) (OTCMKTS:BAYRY), Clovis Oncology, Inc. (NASDAQ:CLVS), Deciphera Pharmaceuticals (NASDAQ:DCPH), BerGenBio ASA (FRA:7BG), Forty Seven (NASDAQ:FTSV), Neon Therapeutics (NASDAQ:NTGN), Gritstone Oncology (NASDAQ:GRTS), OSE Immunotherapeutics SA (OTCMKTS:ORPOF), Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY), Mesoblast Limited (NASDAQ:MESO), Redhill Biopharma Ltd. (NASDAQ:RDHL), Omeros Corporation (NASDAQ:OMER), ADMA Biologics Inc (NASDAQ:ADMA), DBV Technologies S.A. (NASDAQ:DBVT)